Yuflyma, Biosimilar of Humira, Approved for Use in Europe

Yuflyma, Biosimilar of Humira, Approved for Use in Europe

286968

Yuflyma, Biosimilar of Humira, Approved for Use in Europe

The European Commission (EC) has approved Yuflyma (CT-P17), an adalimumab biosimilar, to treat multiple chronic inflammatory diseases, including juvenile idiopathic arthritis. Similar to generics, biosimilars are products that have identical pharmacological properties and are as safe and effective as the original brand-name medications they are based on. However, they tend to be less expensive than their reference products. With this decision, patients with chronic inflammatory disorders living in Europe will now have access to an…

You must be logged in to read/download the full post.